Meeting
2024 ASCO Genitourinary Cancers Symposium
Quality of treatment with targeted agents for advanced prostate cancer by treating specialist.
Authors
Kassem S Faraj
University of Michigan, Ann Arbor, MI
Kassem S Faraj , Mary Oerline , Samuel Kaufman , Megan Veresh Caram , Vahakn B. Shahinian , Brent K. Hollenbeck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 88)
DOI
10.1200/JCO.2024.42.4_suppl.88
Abstract #
88
Poster Bd #
D3
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Quality Care Symposium
Impact of in-house specialty pharmacy on access to novel androgen axis inhibitors in men with advanced prostate cancer.
First Author: Nathan Handley
Poster
2020 Genitourinary Cancers Symposium
Financial hardship among Medicare beneficiaries prescribed oral targeted therapies for advanced prostate cancer.
First Author: Megan Veresh Caram
Poster
2024 ASCO Genitourinary Cancers Symposium
The prognostic value of ductal adenocarcinoma of the prostate in patients with advanced prostate cancer treated with abiraterone acetate.
First Author: Yifu Shi
Poster
2024 ASCO Genitourinary Cancers Symposium
Predicting abiraterone efficacy in advanced prostate cancer: Insights from marker of proliferation Ki-67.
First Author: Fengnian Zhao